NEW YORK – Oncology firm Indivumed said Monday that it has partnered with Biognosys to add proteomic and phosphoproteomic data to its IndivuType multi-omics cancer database.
Under the partnership, Biognosys will use its mass spectrometry technology to profile the proteome and phosphoproteome of clinical samples in Indivumed's database, which also contains genomic, transcriptomic, immunophenotypic, and clinical and outcome data.